Nzisa Mutinga, MD
Nephrology · Columbia, SCNPI 1104891837
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations.
Across 330 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$742
- Otsuka America Pharmaceutical, Inc.$659
- Amgen$575
- Novartis$563
- Fresenius USA Marketing, Inc.$524
- Calliditas Therapeutics US Inc.$492
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,83897%
- Education$1533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 46 | $742 |
| Otsuka America Pharmaceutical, Inc. | 31 | $659 |
| Amgen(2 entities) | 33 | $575 |
| Novartis | 33 | $563 |
| Fresenius USA Marketing, Inc. | 31 | $524 |
| Calliditas Therapeutics US Inc. | 23 | $492 |
| Vifor Pharma, Inc. | 23 | $379 |
| Aurinia Pharma U.S., Inc. | 13 | $269 |
| Bayer | 15 | $247 |
| Travere Therapeutics, Inc. | 10 | $234 |
| Mallinckrodt Hospital Products Inc. | 10 | $200 |
| Akebia Therapeutics Inc | 12 | $187 |
| OPKO Pharmaceuticals, LLC | 11 | $183 |
| GSK | 9 | $160 |
| Sanofi | 5 | $85 |
| Daiichi Sankyo Inc. | 4 | $84 |
| Ardelyx, Inc. | 3 | $72 |
| Alnylam Pharmaceuticals Inc. | 3 | $67 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $53 |
| Lilly USA, LLC | 3 | $44 |
| Cormedix Inc. | 1 | $27 |
| Mallinckrodt Enterprises LLC | 2 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Cvrx, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$5,991 in reported general payments places this provider in the 80th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 78 | $68,116 |
| VelphoroSucroferric Oxyhydroxide | 26 | $63,456 |
| AuryxiaFerric Citrate | 26 | $39,366 |
| ProcritEpoetin Alfa | 39 | $28,358 |
| LokelmaSodium Zirconium Cyclosilicate | 19 | $10,682 |
| JardianceEmpagliflozin | 14 | $10,057 |
| RetacritEpoetin Alfa-Epbx | 24 | $8,101 |
| Calcitriol | 156 | $3,091 |
| Sevelamer Carbonate | 29 | $3,014 |
| Valsartan | 24 | $849 |
| Potassium Chloride | 53 | $835 |
| Losartan Potassium | 59 | $770 |
| Furosemide | 98 | $594 |
| Colchicine | 12 | $593 |
| Allopurinol | 51 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $742 | $78,79897 claims |
| Fresenius USA Marketing, Inc.Velphoro | $524 | $63,45626 claims |
| Akebia Therapeutics IncAuryxia | $187 | $39,36626 claims |
| Boehringer IngelheimJardiance | $14 | $10,05714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Columbia
- Renee EllisColumbia$40K
- Niall McLaughlinColumbia$15K
- Roy MathewColumbia$10K
- Thomas WheelerColumbia$9K
- Rajeev ShenoyColumbia$8K
- Asha BaileyColumbia$5K
- Gregory SmithColumbia$4K
- Abdul UsmaniColumbia$4K
- Carl ShealyColumbia$4K
- David ShureColumbia$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.